

BLAU SYNDROME: KEY INSIGHTS INTO A UNIQUE AUTOINFLAMMATORY DISORDER

ABSTRACT:

Blau syndrome is one of the sporadic auto inflammatory disorders recapitulating early-onset granulomatous inflammation of the skin, joints, and eyes. This hereditary condition is caused by a mutation in the NOD2/CARD15 gene, leading to an imbalance of the innate immune response. An early age of onset characterizes the disease known as Blau syndrome, specifically prevailing before age 4 years. Blau syndrome is characterized by a clinical triad that includes granulomatous dermatitis, symmetric polyarthritis, and recurrent uveitis. Skin involvement consists of small, brownish papules or small plaques. The major joints involved in the wrists, ankles, and hands are affected by arthritis, which can be deformed unless treated. Uveitis may also be severe and may lead to blindness in some cases if left untreated. Diagnosis typically requires a combination of clinical presentation, histopathology, and DNA analysis. Histo-pathological examination usually reveals non-caseating granulomas in skin biopsies. A genetic study showing NOD2 mutations confirms the diagnosis and also differentiates Blau syndrome from other granulomatous conditions. Treatment for Blau syndrome focuses on reducing inflammation and preventing organ damage. Corticosteroids are usually the first line of treatment, but more problematic cases require immunosuppressive/immunomodulatory agents and biological especially TNF- α inhibitors and welfare with these medicines unequivocally offers good prospects. Ongoing follow-up with an ophthalmologist is hence of importance to monitor progression and ensure the adequately timely management of ocular involvement. Even after the recent understanding of its genetic basis and many more pathophysiological mechanisms that lead to Blau syndrome, further research is needed to form targeted treatments to improve long-term outcomes for affected individuals. Awareness about this very rare auto inflammatory disorder must be raised among health professionals at large for its early diagnosis and proper management.

Keywords: Blau syndrome, auto inflammatory disorder, immunosuppressive ,granulomatous,

INTRODUCTION:

Blau syndrome is a rare systemic auto inflammatory disorder characterized by a triad of arthritis, dermatitis, and uveitis. Described firstly by Edward Blau in 1985, the entity is inherited in an autosomal dominant pattern and is typically manifested during early childhood. Knowledge of Blau syndrome is relevant for health professionals, researchers, and, most importantly, affected families since it offers a clear clinical insight into the complex interplay of genes, inflammation, and autoimmunity. Chronic inflammatory syndrome characterized by the clinical triad of granulomatous dermatitis, symmetric arthritis and recurrent uveitis with onset below 4 years of age¹. In the most basic sense, in the case of Blau syndrome, the root lies in the mutations in the NOD2 gene. The gene is highly involved in the functioning of the innate immune system and, most essentially, in the recognition of bacterial peptidoglycans, inducing the proper repertoire presented immunologically. Atypical cases of BS have been reported with involvement of organs other than skin, joint and eyes². Therefore, when mutations occur in NOD2, deregulation at the inflammatory response level leads to typical Blau syndrome symptoms. The hallmark characteristic of Blau syndrome is the formation of non-caseating granulomas in tissues throughout the body. Granulomas are collections of abnormal inflammatory cells that often replace normal tissue and result in a combination of characteristic signs and symptoms. Let's consider each part of this triad in more detail:



Fig 1 : Morphology of the syndrome

1. **Granulomatous Arthritis:** This is usually the initial and main presentation feature of Blau syndrome. The involved joints are frequently many, and symmetrical, and mostly beginning in early childhood. In Blau syndrome, arthritis is generally dominated by synovitis and the presence of granulomas within the synovial tissue. Common sites of involvement include the wrists, ankles, knees, and elbows. With untreated chronic inflammation, deformities of the joint can result in functional disability.
2. **Dermatitis:** Skin involvement in Blau syndrome most commonly occurs as a characteristic rash. It is classically a tan-colored, scaly eruption that is only slightly pruritic. There is a general distribution over the trunk and extremities, with some symmetry. Histologically, the lesions of the skin show non-caseating granulomas within the dermis.
3. **Uveitis:** Ocular inflammation is a significant cause of concern with Blau syndrome, and in its less favorable state of management, there are fair chances of losing vision. Uveitis in Blau

syndrome normally presents bilaterally and prominently involves both the anterior and posterior chambers of the eye. Intraocular, it shows the presence of granulomatous lesions giving further rise to complications like cataracts, glaucoma, and retinal detachment.



FIG2 : Uveitis-Ocular inflammation syndrome




FIG 3: Dermatitis: Skin involvement in Blau

Although these three features constitute the classic triad of Blau syndrome, it must be kept in mind that it could affect other organ systems too. Some patients might even develop granulomatous inflammation in the liver, kidneys, lungs, or even the central nervous system. This possibility of multisystem involvement endorses the need for a comprehensive approach to the care and follow-up of these patients. The diagnosis of Blau syndrome is difficult mostly because of its rarity and due to its presentation being similar to a variety of other inflammatory conditions. It can be diagnosed by careful clinical evaluation and taking of a family history and, where possible, genetic testing. Genetic testing may identify NOD2 mutations confirming the diagnosis. However, it must be stated that not all patients who have clinical features of Blau syndrome will have detectable NOD2 mutations, which suggests that it is genetically heterogeneous. Most treatment strategies for Blau syndrome focus on the control of inflammation and the reduction of destruction in organs. Systemic corticosteroids are the conventional pharmacological agents and can control acute inflammatory flares. However, their long-term side effects are significant and are used with caution in growing children, so most often a steroid-sparing agent is used in Blau syndrome. Some immunosuppressive and

immunomodulatory medications, such as methotrexate, azathioprine, and mycophenolate mofetil, have had some success in taming the disease. More recently, biological agents, particularly TNF- α inhibitors like infliximab and adalimumab, have also been explored with promising success in the treatment of Blau syndrome. These target specific components of the inflammatory cascade and have been shown to be effective in the management of the joint, skin, and ocular manifestations of this disease. The management of Blau syndrome in the face of its chronicity, potential multisystem involvement, and risk of long-term complications prove to be difficult despite all these therapeutic modalities. Patients with Blau syndrome normally warrant multidisciplinary management. Patients are managed by the rheumatologist, dermatologist, and ophthalmologist along with other specialists involved in the collaborative approach for the Blau syndrome patient. Research on Blau syndrome continues to advance the understanding of autoinflammatory disorders and the intricate role of the innate immune system in health and disease. Research has also continued on the molecular mechanisms of NOD2 mutations with respect to their effect on cellular function. This line of research is important not only for understanding Blau syndrome but also for other granulomatosis and inflammatory diseases. This goes beyond the study of Blau syndrome alone, as it offers a model of understanding the relationship between the genetic background and triggering environmental factors. In many aspects, this knowledge could further establish treatment protocols not only with respect to Blau syndrome per se but to other, related conditions as well. Blau syndrome is a high uniqueness and ultra-challenge auto inflammatory disorder, itself an example serving to underline a more complex knob of gene regulation that eventually leads to an immune response. In this condition, the triad of arthritis, dermatitis, and uveitis, together with possible systemic involvement in multiple organ systems, necessitates close monitoring and tailor-made treatment strategies. The complexities of this condition are being unraveled with ongoing research, and it is hoped that better diagnostic tools will be available, as well as more effective therapy and ultimately, better outcomes for patients with this rare group of conditions..

2. MATERIALS & METHODS:

SEARCH STRATEGY

Relevant literature available on these sources has been reviewed. We consider only observational research, including retrospective data analysis, cohort, and case-control study designs. This strict selection process was aimed at increasing the rigor and reliability of the results by making sure that only papers matching the pre-defined characteristics should be included in the article. This rigorous selection method sought to enhance the rigor of its findings and results by guaranteeing that only papers of predefined characteristics made it through to the article. It was meant to establish a body of studies that would provide insightful information about the different dimensions involved in the management of sepsis using quite a strict screening and inclusion process. This would therefore enhance the body of knowledge in any crucial area of healthcare. Ultimately, it is the systematic search of these databases and careful appraisal of relevant studies that made this thorough review possible for a significant addition to the body of knowledge on disease and its consequences for clinical practice and patient outcomes.

Inclusion

We assessed only the studies of sepsis patients that were observational in design (either cohort or case-control) or analyzed retrospective data to be included. These were the kinds of studies that observed what might happen in some patients.

Exclusion

I ignored the case reviews and reports. Apart from that, the studies that did not provide data on the relevant outcomes or did not present findings comparing.

3. RESULT AND DISCUSSION:

Blau syndrome is a very rare autoinflammatory disorder that is characterized by the triad of granulomatous arthritis, uveitis, and dermatitis. Edward Blau first described this syndrome in 1985, which opened a doorway for subsequent research studies on the genetic basis of this disorder. This disorder is genetic and does not just relate to one part of the body but to many because it encompasses many organ systems that hold host to a good number of symptoms and complications. More commonly, it is actually through early childhood that these symptoms

present, indicating recognition at an early age as well as the need for early interventions. Blau syndrome is an extremely rare condition, and because of this fact, awareness of the condition among medical professionals and affected families seems to be essential. Medical care providers can enhance early recognition and consult clear management strategies when they become acquainted with clinical signs and diagnostic criteria for Blau syndrome. Early diagnosis with efficient management strategies would help to improve the quality of life of patients with Blau syndrome. The above underlines the significant reason for future research in looking deeper at the pathophysiology of the disorder and fine-tuning therapeutic interventions. Blau syndrome is a genetic disorder. Specific mutations in the NOD2 gene, also called CARD15, have been shown to play a role in the recognition of bacterial peptide-glycan. The gene mediates the induction of the NF- κ B pathway within the cellular innate immune system. The main highlights of the crucial role of the NOD2 gene in maintaining immune homeostasis underline the NF- κ B pathway, which prepares inflammatory responses and immune reactions.

Inheritance Patterns: Blau syndrome follows an autosomal dominant pattern of inheritance. That means that there is a 50% probability that an offspring will inherit the mutated gene should either of the parents be carrying it. But this is a rule with certain known exceptions; some cases of Blau syndrome represent de novo mutations. In cases of de novo mutations, spontaneous genetic alteration is unlinked to either parent. The sporadic nature of these occurrences explains the complexity of genetic disorders and underlines the requirement of detailed genetic counseling and research for understanding the etiology of diseases.

Clinical Manifestations;

a) Granulomatous Arthritis:

- The disease is generally poly-articular, involving most commonly the bilateral ankles, wrists, and knees of the affected person.
- It could present as a symmetrical poly-arthritis.
- Swelling, stiffness, and restricted movement of the affected joints.
- Deformities might develop in acute cases.

b) Uveitis:

- Inflammation of the eye's middle coating, or uvea.
- In a chronic case, presentation is most commonly bilateral and could be either anterior, intermediate, or panuveitis.
- Pain and redness in the eyes, photophobia, blurry vision with systemic symptoms
- Cataract, Glaucoma, Complications
- Skin rash - may be tan-colored or erythematous papules
- Commonly involves the trunk and extremities
- Erythema can be scaly and ichthyosis-like

Other Symptoms and Signs:

a) Fever: Recurrent and low-grade fever

b) Camptodactyly: Deformity of the fingers where they are in a fixed flexed position, especially the little finger

c) Tenosynovitis: Inflammation of tendon sheaths, usually in the hands and feet

d) Lymphadenopathy: Swollen lymph nodes, Rare cranial neuropathies or central nervous system involvement

g) Cardiovascular involvement: Rare arthritis, pericarditis

h) Pulmonary manifestations: Interstitial lung disease, lung granulomas

Age of Onset and Progression:

Usually before 4 years of age

The triad of symptoms doesn't always show at the same time; arthritis usually appears first

The course of the disease is chronic and could be progressive in a non-treated state

SEVERITY AND COURSE MAY VARY MARKEDLY FROM PERSON TO PERSON.

Effects on Growth and Development

In children may give delays in growth or short stature

Involvement of joints can lead to altered growth and mobility.

Systemic Inflammation:

An increase in inflammatory markers is frequently noticed - ESR, CRP

Chronic inflammation can cause long-term damage.

Blau syndrome is an extremely rare genetic condition that heralds a classical triad of clinical manifestations, typically developing in affected individuals. By far, the most characteristic clue to a diagnosis of this condition would be granulomatous arthritis, a pattern of joint inflammation that typically starts during early childhood, and occurs before the age of 4 years. A handful of joints, such as the wrists, ankles, and knees, are quite commonly affected by this arthritic process. During the course of this illness, the joints will eventually display observative signs such as swelling, tenderness, and restricted movement, which may eventually result in erosive changes in the joints and functional disabilities.

Aside from arthritis, one of the cardinal manifestations of Blau syndrome is the development of uveitis, an inflammation involving the uvea or the middle layer of the eye. Uveitis usually manifests with redness of the eyeball, eye pain, sensitivity to light, and dimness of vision. If untreated, uveitis may eventually lead to cataracts and glaucoma or even vision loss or blindness. It is therefore essential to promptly recognize and treat these ocular features to maintain vision and avert long-term complications in Blau syndrome.

Dermatitis is inflammation of the skin. The appearance in general is of a scaly, tan rash, which tends to appear mostly on the trunk and extremities. This skin disease can also be identified by subcutaneous nodules. These are small, firm lumps under the skin surface. The extent to which this rash causes itchiness and discomfort can make it very irritating and distressing for patients. Considering that it tends to cause dryness and flakiness, especially in the affected areas by dermatitis, having a particularly characteristic embarrassment can greatly influence a person's life and affect the operations of daily work and activities. It is thus important to properly diagnose and manage dermatitis for the reduction of symptoms and the health of the skin. Apart from fever, camptodactylia, and cranial neuropathies which are characteristic hallmarks of

Blau syndrome, this complex disease may show its involvement in other organ systems with a wide array of supplementary symptoms and complications. More specifically, the supplementary manifestations and complications of Blau syndrome include interstitial lung disease, arthritis, renal involvement, and hepatosplenomegaly. The numerous, diverse manifestations only underline this systemic nature, showing what kind of dramatic effect it is capable of across many body compartments. Blau syndrome complicated both diagnoses involving various organs and management, but more importantly, it underscored the need for comprehensive care that shall help address the divergent aspects of this disorder. Education and awareness of Blau syndrome, for one, must be on the part of a myriad of possibilities of the said condition, which they have to watch in their practice, bearing in mind that its implications go beyond the usual expected characteristics. The diagnosis of Blau syndrome is one of the rare conditions and poses a considerable challenge. The reason is that since it may share some of the similar symptoms with some other inflammatory disorders, a holistic approach to its diagnosis would be most appropriate.

Generally, steps in the diagnostic process would include the following:

A detailed clinical assessment starts with searching for the classic triad of symptoms that determine the characteristics of Blau syndrome and lead a physician to the possibility of its diagnosis. It is important not to disregard the necessity of having a good family history because this condition has genetic involvement. Often, the clues from familial genetics may help give answers to the diagnostic puzzle.

- Advanced imaging modalities, like X-rays, MRI, and ultrasound, are the mainstay of around-the-joint manifestations and can pick out specific changes indicative of Blau syndrome, thus increasing the diagnostic accuracy and management of the patient.
- Finally, an ophthalmic assessment will be called for to thoroughly evaluate and follow up on the potential ocular involvement that might be a part of the whole spectrum of the disease and its varied influence on different organ systems.
- A skin biopsy can reveal the formation of non-caseating granulomas, a typical pathophysiological process in Blau syndrome, and aids in the confirmation of diagnosis.

- Genetic testing can be considered as the next diagnostic tool following NOD2 gene mutations, eventually providing definitive proof of Blau syndrome and facilitating appropriate management in an individual patient.

Furthermore, the importance of differential diagnosis in this condition cannot be overstressed, as Blau syndrome has many clinical features in common with juvenile idiopathic arthritis, sarcoidosis, and other auto-inflammatory disorders; hence, a strict and thorough strategy is needed for the correct differential diagnosis among these entities. Blau syndrome is among the very rare types of autoimmune disorders in which a definitive cure has not yet been found. The adaptation of a workable treatment modality for this syndrome is decentralized upon meticulous management of its myriad symptoms and preventive measures against the possible complications. In view of the complex nature of symptoms associated with Blau syndrome, which is multi-dimensional, such treatment usually requires an approach that integrates experts in medicine from various specializations. Systemic inflammatory manifestations are managed by rheumatologists, and the ophthalmologists monitor ocular ones, which are a common feature of the disorder in affected individuals. Dermatologists may also be called on to manage skin-associated symptoms that may develop over the course of the disease. Working together with all these different kinds of experts allows for holistic care approaches to the patient with Blau syndrome, ensuring that all aspects of the syndrome are treated under one umbrella with an individualized, integrated treatment plan. An active multidisciplinary team can ensure optimum healthcare for persons with Blau syndrome by seeking the best quality of life and minimizing the debilitating effects of this disorder.

For the management of Blau syndrome, healthcare providers can consider several treatment strategies to deal with the diverse symptoms and implications of this condition. One crucial way of managing the condition is by the use of drugs, including over-the-counter non steroidal anti-inflammatory medications, which come in handy for managing pain and inflammation and are highly beneficial when taken by persons with mild symptoms. In addition, corticosteroids are frequently systematically or topically administered to lower inflammatory reactions, notably during flares of the disease, although with careful deliberation of the potential long-term side effects of protracted steroid administration. DMARDs are frequently advised mainly as a steroid-

sparing measure and for the better management of arthritis in Blau syndrome. In patients unresponsive to traditional treatments, reasonable results have been achieved in controlling disease progression by using biological agents such as TNF- α inhibitors (infliximab, adalimumab, or etanercept). Very occasionally, judicious immunosuppressant with mycophenolate mofetil or tacrolimus works well in some cases of Blau syndrome. Along with pharmacologic treatments, supportive care measures such as physical therapy and occupational therapy, including the use of assistive devices in treatment plans, are critical modalities of a holistic management approach. All of these combined therapeutic modalities are aimed at one goal: diminishing joint-related issues, restoring functional capabilities, and taking steps toward pacifying the quality of life in Blau syndrome-affected patients.

Long-term follow-up with regular monitoring of disease activity is important for reassessment and treatment modification if indicated. Special attention should be given to ophthalmological examination, given the potential ocular complications that could threaten eyesight.

Future Directions in Research

The rarity of the disease places special and complex challenges on research and development of effective treatment for Blau syndrome. In the latter, the main areas of concern are those deriving from current medical research about the detection of the genetic mechanisms responsible for mutations in the NOD2 gene in the development of a disease and pointing out new targets for therapeutic interventions. Besides, scientists worldwide are also battling to find dependable biomarkers that will radically alter the means for diagnosing, monitoring, and assessing the outcomes therapeutically for patients with Blau syndrome. In turn, the above-described approaches, such as the studies of new therapies, including modern biological agents and sets of therapies, hold great promise for granting more effective, yet safer means for the management of the disease. With more patients being accurately diagnosed and then followed longitudinally, one gathers great information on the long-term prognosis and the effect of treatment from different modalities, with the outcome of continuously defining the best mode of care. Indeed, in conditions like Blau syndrome and other rare disorders, international collaboration and a patient registry are especially important for large-scale study and data collection.

Living with Blau Syndrome

Life with Blau syndrome is generally difficult for the victims and their families alike. A logical way to interpret it is that, besides the physical symptoms that, by and large, characterize the disease, it deeply affects the psychological and social well-being of the patients and, therefore, multifarious supporting systems are required. Involvement with support groups and advocacy organizations for patients becomes a very important factor in empowering the affected with relevant information and supportive resources and belonging to a community that is going through similar challenges. Recognition of the key role that education plays is very important, not only for the patients and their families but also for those healthcare providers who might not be well-versed in this rare disorder. The result is that early diagnosis of Blau syndrome and the application of more tailored and useful management strategies can be greatly helped by heightened awareness and knowledge dissemination alone. Blau syndrome is indeed a rare auto inflammatory disorder. However, it became an important model concerning the understanding of the complexity of auto inflammatory disorders and their interplay with the subject at hand: genetics. With this systemic condition, it contributes significantly to the mechanisms of inflammation and the regulation of immune responses.

Recent advances in genetic testing have significantly enhanced the diagnosis of the condition in those affected with Blau syndrome, even allowing the possibility of early identification and of creating more specific treatment strategies. Ongoing treatment development provides hope for a more effective strategy for curing the disease. However, timely identification, the optimal definition of treatment protocols, and the long-term establishment of favorable outcomes remain difficult in affected individuals. Additional studies would be the key to a better prognosis for patients diagnosed with Blau syndrome. If our base of knowledge were to deeply widen, sponsored by the joint commitment of researchers, professionals in healthcare, and gymnastics by organizations that represent patients, prospects would greatly improve for a better diagnosis, treatment modalities, and quality of life of those afflicted by this rare but impactful disorder.

CONCLUSION:

Blau syndrome is a very rare auto inflammatory disorder, with typical clinical manifestations such as granulomatous inflammation and systemic symptoms. The understanding of this illness

is quite significant for its early diagnosis and proper management, thus considerably improving the prognosis for the involved patients. Further research on the mechanisms of genetics and therapeutic interventions is therefore needed to improve the knowledge and treatment of these conditions for the affected individuals. We can do this by informing and making people in different fields of expertise work together to help those who are suffering from Blau syndrome, thus moving further in this area of auto inflammatory disorders.

Ethical Approval:

As per international standards or university standards written ethical approval has been collected and preserved by the author(s).

Consent

As per international standards or university standards, patient(s) written consent has been collected and preserved by the author(s).

Disclaimer (Artificial intelligence)

Option 1:

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of manuscripts.

Option 2:

Author(s) hereby declare that generative AI technologies such as Large Language Models, etc have been used during writing or editing of manuscripts. This explanation will include the name, version, model, and source of the generative AI technology and as well as all input prompts provided to the generative AI technology

Details of the AI usage are given below:

- 1.
- 2.
- 3.

REFERENCES:

1. Paolo Sfriso , Francesco Caso , Sofia Tognon , Paola Galozzi , Alessandra Gava , Leonardo Punzi., Blau syndrome, clinical and genetic aspects , Volume 12, Issue 1, November 2012, Pages 44-51 science direct.
2. Punzi , Alessandra Gava , Paola Galozzi , Paolo Sfriso ., Blau syndrome Leonardo . Volume 25, Issue 5, October 2011, Pages 703-714 Science direct.
3. Carine H Wouters , Anne Maes , Kevin P Foley., Blau Syndrome, the prototypic auto-inflammatory granulomatous disease . 2014, volume 12 issue 33 <http://www.ped-rheum.com/content/12/1/33>.
4. CARD15 mutations in Blau syndrome Published online: 27 August 2001, DOI: 10.1038/ng720.
5. Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes . Volume 54, Issue 6, June 2015, Pages 1008–1016, <https://doi.org/10.1093/rheumatology>.
6. Krati Chauhan , Clement Michet., A Case of Blau Syndrome . 04 May 2014 <https://doi.org/10.1155/2014/216056>.
7. Rose, Carlos D.; Martin, Tammy M.; Wouters, Carine H., Blau syndrome revisited . 2011 volume 23 , issue 5, t 7/12/24, 12:07 https://journals.lww.com/corheumatology/abstract/2011/09000/blau_syndrome_revisited.2.aspx.

8. Stephen A. Raphael,; Edward B. Blau, ; Wan Hua Zhang., Analysis of a Large Kindred With Blau Syndrome for HLA, Autoimmunity, and Sarcoidosis. 1993, <http://doi:10.1001/archpedi.1993.02160320044017>.
9. Leonardo Punzi , Antonio Furlan , Marta Podswiadek , Alessandra Gava , Marialuisa Valente , Mario De Marchi , Andrea Peserico., Clinical and genetic aspects of Blau syndrome: A 25-year follow-up. Volume 8, Issue 3, January 2009, Pages 228-232.
10. Marjan M van Duist, Mario Albrecht, Marta Podswiadek, Daniela Giachino, Thomas Lengauer, Leonardo Punz ., A new CARD15 mutation in Blau syndrome .2005, volume 13, 742–747 (2005).
11. Katherine P. Kaufman, Mara L. Becker, M., Distinguishing Blau Syndrome from Systemic Sarcoidosis 2021, 2021 Feb 9. doi: 10.1007/s11882-021-00991-3. PMC9762981 .
12. Hanene Lassoued Ferjani, Lobna Kharrat , Dorra Ben Nessib, Dhia Kaffel., Management of Blau syndrome: review and proposal of a treatment algorithm. 2023 Volume 183, pages 1–7,(2024)
13. Mara L. Becker & Carlos D. Rose ., Blau syndrome and related genetic disorders causing childhood arthritis . December 2005 Volume 7, pages 427–433,(2005).
14. Rosenbaum, Michael P Davey and Tammy M Martin Carlos D Rosé, Trudy M Doyle, Gail McIlvain-Simpson., Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous 2005, Volume 32, issue 2 <http://www.jrheum.org/content/32/2/373> J Rheumatol2005;32;373-375.

15. Inge L. Sarens , Ingele Casteels , Jordi Anton , Brigitte Bader-Meunier., Blau Syndrome - Associated Uveitis: Preliminary Results from an International Prospective Interventional Case Series. 2017,American journal of ophthalmology.
16. Li Lu , Min Shen , Dongbin Jiang , Yanmin Li , Xiaolong Zheng., Blau syndrome with good Responses to Tocilizumab. volume 47, Issue 5, April 2018, Pages 727-731.
17. Tammy M. Martin, Zili Zhang, Paul Kurz, Carlos D. Rose, Hong Chen ., The NOD2 defectin Blau syndrome does not result in excess interleukin activity .2010 volume 60 , issue 2 doi: 10.1002/art.24222.
18. Rajni Kumrah , Rakesh Kumar Pilonia , Nitin Kumar Menia., Blau syndrome: Lessons learned in a tertiary care centre at Chandigarh, North India. 15 September 2022 Volume 13 - 2022 | <https://doi.org/10.3389/fimmu.2022.932919>.
19. Jing Chen, Yi Luo¹ , Mengzhu Zhao , Di Wu, Yunjiao Yang., Effective treatment of TNF α inhibitors in Chinese patients with Blau syndrome . 2019 volume 21:236 <https://doi.org/10.1186/s13075-019-2017-5>.
20. Toru Kurokawa , Takanobu Kikuchi , Kouichi Ohta , Hiroki Imai , Nagahisa Yoshimura., Ocular manifestations in Blau syndrome associated with a CARD15/Nod2 mutation . Volume 110, Issue 10, October 2003, Pages 2040-2044. [https://doi.org/10.1016/S0161-6420\(03\)00717-6](https://doi.org/10.1016/S0161-6420(03)00717-6).
21. Kalpana Babu , Anand P Rao ., Clinical Profile in Genetically Proven Blau Syndrome: A Case Series from South India Pages 250-256 28 Nov 2019, Accepted 19 Mar 2020, Published online: 15 Apr 2020.
22. Rose CD, Wouters CH. Auto inflammatory Granulomatous Disease: Blau Syndrome. Textbook of auto inflammation. 2019:367-81.